Last updated: 2026-09-08 14:10:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Dyne Therapeutics, Inc. (DYN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $18.47, with a market capitalisation of $4.53B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $11.92 to $27.31. This page covers its latest market performance, valuation, price trends and company information.
$4.53B | |
$17.08 | |
$47.45 | |
$0.30 | |
$24.28 | |
3.72M | |
2.23M | |
-- | |
$27.31 | |
$11.92 | |
-- | |
-- |
Dyne Therapeutics, Inc. (DYN) is currently trading at $18.47 as of 2026-09-08 13:54:40, down 23.95% ($5.81) from the previous close of $24.28
During today's regular trading session, DYN has traded between $0.30 and $47.45, with a trading volume of 3.72M shares. The current price is near the middle of today's range.
Over the past seven days, Dyne Therapeutics, Inc. (DYN) moved from $26.09 to $18.47, representing a decline of 29.22% ($7.62).
The stock traded between $15.00 and $26.49 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.69 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 42.5%
DYN is currently trading at $18.47, placing it 42.5% of the way from its 52-week low of $11.92 to its 52-week high of $27.31. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 258 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Dyne Therapeutics, Inc. (DYN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.